Scientific article

Administration d'albumine lors de paracentèse évacuatrice dans la cirrhose : dogme ou évidence ?

Published inRevue médicale suisse, vol. 8, no. 358, p. 1956,1958-1960
Publication date2012

Large-volume paracentesis is the procedure of choice for refractory or symptomatic ascitis. However, there is a risk for Post-paracentesis Circulatory Dysfunction (PCD) leading to hyponatremia, renal failure, or worsening portal hypertension. PCD may be effectively prevented by volume expanders, essentially albumin, administered during and after the procedure, but the data regarding the impact of this treatment on mortality are still limited. For this reason, there is a debate about the true clinical benefit of preventing PCD, explaining some variations among published guidelines. The efficacy of molecules other than albumin is still under study but none has shown real superiority so far.

  • Albumins/therapeutic use
  • Ascites/etiology/therapy
  • Cardiovascular Diseases/prevention & control
  • Humans
  • Liver Cirrhosis/complications
  • Paracentesis/adverse effects
Citation (ISO format)
MANZOCCHI BESSON, Sara, NENDAZ, Mathieu, SPAHR, Laurent François Joséph. Administration d’albumine lors de paracentèse évacuatrice dans la cirrhose : dogme ou évidence ? In: Revue médicale suisse, 2012, vol. 8, n° 358, p. 1956,1958–1960.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation04/03/2014 11:47:00 AM
First validation04/03/2014 11:47:00 AM
Update time03/14/2023 9:05:21 PM
Status update03/14/2023 9:05:21 PM
Last indexation05/02/2024 1:57:16 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack